Clinical trial · Observational
Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
Study Aiming at Researching Diagnostic Markers for the Recognition of Precancerous States, Tracking, Follow-up, and the Identification of New Therapeutic Targets for Mesothelioma in Patients With Atypical Mesothelial Hyperplasia.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at mesothelin and osteopontin as diagnostic markers in patients with mesothelioma or atypical hyperplasia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Mesothelioma | Malignant Mesothelioma | ONTOLOGY_EXACT | 0.98 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| study of high risk factors | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Mesothelin and osteopontin concentrations in serum
Secondary outcomes (3)
- measure
- Cytological, histological, immunohistochemical, and molecular markers of precancerous disease in tissue samples
- measure
- Role of SV40
- measure
- Relationship of serum concentration of mesothelin and/or osteopontin with the expression of other markers and with clinical progression
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
Inclusion criteria:
* Diagnosis of mesothelial hyperplasia and meeting 1 of the following criteria:
* Confirmed prior exposure to asbestos and presence of pleural effusion and meets 1 of the following diagnostic criteria:
* Mesothelioma
* Mesothelial hyperplasia of unspecified malignancy
* Reactional inflammatory hyperplasia
* No asbestos exposure but pleural effusion with pleural malignant mesothelioma or pulmonary metastasis
* Prior exposure to asbestos, no pleural effusion, and asymptomatic (pleural plaques present)
* No prior exposure to asbestos but with benign pleural effusion
* Tissue obtained by pleuroscopy, surgical biopsy, or video-thoracoscopy available
* Paraffin-embedded and frozen tissue available
Exclusion criteria:
* Solitary fibrous tumor
* Diffuse pleural fibrosis
* Purulent pleurisy
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* No prior chemotherapy or radiotherapyReferences
Publications (0)
Data not yet available